Arix Bioscience PLC (ARIX)
Arix Bioscience plc
Imara announces pricing of public offering
LONDON, 14 July 2021: Arix Bioscience plc ("Arix", LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, notes that its portfolio company Imara Inc. (Nasdaq: IMRA), has announced the pricing of its previously announced underwritten public offering of shares of its common stock at a public offering price of $6.00 per share, for gross proceeds of $50 million, before underwriting discounts and commissions and offering expenses. The offering is expected to close on 16 July 2021, subject to customary closing conditions. All shares are being offered by Imara. In addition, Imara has granted the underwriters an option for a period of 30 days to purchase up to $7.5 million of additional shares of its common stock at the public offering price, less underwriting discounts and commissions.
Arix has agreed to invest $8.0 million (£5.8 million) in the offering to retain a stake of approximately 9.0% in Imara (amounting to 2,344,072 ordinary shares).
The announcement can be accessed on Imara's website at https://ir.imaratx.com/press-releases and full text of the announcement from Imara is contained below.
For more information on Arix, please contact:
Arix Bioscience plc
Charlotte Parry, Head of Investor Relations
+44 (0)20 7290 1072
Optimum Strategic Communications
Mary Clark, Manel Mateus
+44 (0)20 3922 1906
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com
Imara Announces Pricing of Public Offering
BOSTON, July 13, 2021 -- Imara Inc. (the "Company") (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, announced the pricing of its previously announced underwritten public offering of shares of its common stock at a public offering price of $6.00 per share, for gross proceeds of $50 million, before underwriting discounts and commissions and offering expenses payable by the Company. The offering is expected to close on July 16, 2021, subject to customary closing conditions. All shares are being offered by the Company. In addition, the Company has granted the underwriters an option for a period of 30 days to purchase up to $7.5 million of additional shares of its common stock at the public offering price, less underwriting discounts and commissions.
Morgan Stanley, SVB Leerink and Cantor are acting as joint book-running managers for the offering.
The shares are being offered by the Company pursuant to a shelf registration statement that was filed with the Securities and Exchange Commission (the "SEC") on April 1, 2021 and declared effective on April 8, 2021. This announcement does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.
The securities referred to in this release are to be offered only by means of the prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement relating to, and describing the terms of, the offering has been filed with the SEC and is available on the SEC's web site at www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus relating to this offering can be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at email@example.com; or SVB Leerink LLC, One Federal Street, 37th Floor, Boston, Massachusetts, 02110, Attention: Syndicate Department, by telephone at (800) 808-7525, ext. 6105, or by email at firstname.lastname@example.org.
 At exchange rate on 13 July 2021
3.1. Additional regulated information required to be disclosed under the laws of a Member State
EQS News ID:
End of Announcement
EQS News Service